Harbeck N - Search Results

1

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S. von Minckwitz G, et al. Among authors: harbeck n. J Clin Oncol. 2013 Oct 1;31(28):3531-9. doi: 10.1200/JCO.2012.47.2167. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980081 Clinical Trial.

2

[Possibilities in immunocytochemistry exemplified by bone marrow aspiration cytology in patients with breast carcinoma].

Eiermann W, Harbeck N, Untch M. Eiermann W, et al. Among authors: harbeck n. Gynakologe. 1990 Dec;23(6):358-64. Gynakologe. 1990. PMID: 2177719 German. No abstract available.

3

[Micrometastases in bone marrow at the time of primary treatment of breast cancer: a new prognostic criterion?].

Untch M, Harbeck N, Eiermann W. Untch M, et al. Among authors: harbeck n. Gynakol Rundsch. 1989;29 Suppl 2:231-3. Gynakol Rundsch. 1989. PMID: 2693244 German. No abstract available.

4

Micrometastases in bone marrow in patients with breast cancer.

Untch M, Harbeck N, Eiermann W. Untch M, et al. Among authors: harbeck n. Br Med J (Clin Res Ed). 1988 Jan 23;296(6617):290. doi: 10.1136/bmj.296.6617.290. Br Med J (Clin Res Ed). 1988. PMID: 3124916 Free PMC article. No abstract available.

5

Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.

Harbeck N, Untch M, Pache L, Eiermann W. Harbeck N, et al. Br J Cancer. 1994 Mar;69(3):566-71. doi: 10.1038/bjc.1994.103. Br J Cancer. 1994. PMID: 7510120 Free PMC article.

6

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Harbeck N, Kates RE, Schmitt M. Harbeck N, et al. J Clin Oncol. 2002 Feb 15;20(4):1000-7. doi: 10.1200/JCO.2002.20.4.1000. J Clin Oncol. 2002. PMID: 11844823

7

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Harbeck N, et al. Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417

8

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

9

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Zemzoum I, et al. Among authors: harbeck n. J Clin Oncol. 2003 Mar 15;21(6):1022-8. doi: 10.1200/JCO.2003.04.170. J Clin Oncol. 2003. PMID: 12637466

10

Detection and clinical implications of early systemic tumor cell dissemination in breast cancer.

Pantel K, Müller V, Auer M, Nusser N, Harbeck N, Braun S. Pantel K, et al. Among authors: harbeck n. Clin Cancer Res. 2003 Dec 15;9(17):6326-34. Clin Cancer Res. 2003. PMID: 14695131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

689 results

Search Page